{"result": "(\"entity\"<|>GEN SRY<|>GENE<|>The SRY gene is involved in the differentiation of Sertoli cells and the development of testes, crucial for male sexual development.)\n##\n(\"entity\"<|>SÍNDROME POLIGLANDULAR AUTOINMUNE<|>EVENT<|>An autoimmune syndrome that may affect the development of gonads and is associated with various hormonal imbalances.)\n##\n(\"entity\"<|>KLINEFELTER SYNDROME<|>EVENT<|>A genetic condition that affects males, characterized by the presence of an extra X chromosome, leading to various physical and reproductive issues.)\n##\n(\"entity\"<|>AZF<|>GENE<|>The AZF region is a genetic factor associated with azoospermia, which is the absence of sperm in semen.)\n##\n(\"entity\"<|>TESTOSTERONE<|>HORMONE<|>A hormone that plays a key role in male development and reproductive function, often treated in cases of deficiency.)\n##\n(\"entity\"<|>DSD<|>EVENT<|>Developmental Sexual Disorder (DSD) refers to a group of conditions involving atypical development of physical sex characteristics.)\n##\n(\"entity\"<|>GINECOMASTIA<|>CONDITION<|>A condition characterized by the enlargement of breast tissue in males, often associated with hormonal imbalances.)\n##\n(\"entity\"<|>AZOOSPERMIA<|>CONDITION<|>A medical condition characterized by the absence of sperm in the ejaculate, often leading to infertility.)\n##\n(\"relationship\"<|>GEN SRY<|>SÍNDROME POLIGLANDULAR AUTOINMUNE<|>The SRY gene is involved in sexual differentiation, which can be affected in autoimmune syndromes<|>5)\n##\n(\"relationship\"<|>KLINEFELTER SYNDROME<|>GEN SRY<|>Klinefelter syndrome is related to the presence of an extra X chromosome, which can affect the expression of the SRY gene<|>6)\n##\n(\"relationship\"<|>AZF<|>AZOOSPERMIA<|>The AZF region is directly linked to the condition of azoospermia, affecting male fertility<|>8)\n##\n(\"relationship\"<|>TESTOSTERONE<|>DSD<|>Testosterone treatment is often necessary for individuals diagnosed with DSD to manage symptoms and promote male characteristics<|>7)\n##\n(\"relationship\"<|>GINECOMASTIA<|>TESTOSTERONE<|>Ginecomastia can occur as a side effect of testosterone deficiency or treatment<|>4)\n##\n(\"relationship\"<|>AZOOSPERMIA<|>TESTOSTERONE<|>Azoospermia is often treated with testosterone therapy to address hormonal imbalances<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: característica que define el síndrome es el desarrollo testicular en individuos con 46 cromosomas, dos de ellos X y sin presencia de cromosoma Y normal en la mayoría de sus líneas celulares. No obstante, el paciente ha de tener material procedente del gen Y más o menos evidente, ya que el gen SRY (región Y determinante del sexo) está involucrado en la diferenciación de las células de Sertoli y en el desarrollo de los testículos. En la profase de la primera división meiótica paterna de varones 46,XX con alteraciones de la diferenciación sexual surgen translocaciones del gen SRY del cromosoma Y al cromosoma X en más del 80% de pacientes (gen SRY-positivos). Suele tratarse de casos aislados, pero también hay descritos casos hereditarios autosómicos dominantes. Para confirmar el diagnóstico se puede determinar el gen SRY (sex-determining region of the Y chromosome).\n\nEn el resto de varones SRY-negativos, el mosaicismo del gen SRY podría estar oculto. Se ha sugerido un patrón de herencia autosómico recesivo. La patogenia de la enfermedad en pacientes SRY negativos también se ha asociado con la sobreexpresión de genes (SOX9, SOX3, etc.) responsables del desarrollo de genitales masculinos o la inadecuada expresión génica (WNT4, RSPO1, etc.) responsable del desarrollo de los genitales femeninos. En algún caso se han descrito mutaciones del gen RSPO1, que codifica la R-espondina 1 en pacientes con hiperqueratosis palmoplantar y carcinoma de células escamosas, que es un factor represor del desarrollo testicular.\n\nAproximadamente el 85% de los pacientes con desarrollo sexual diferente (DSD) no sindrómico testicular 46,XX son diagnosticados después de la pubertad. Estos pacientes presen-\n---\n# GÓNADAS, SÍNDROME POLIGLANDULAR AUTOINMUNE Y MISCELÁNEA\n\ntan vello púbico y tamaño del pene normales, pero testículos pequeños, ginecomastia y esterilidad por azoospermia. El otro 15% presenta, al nacer, genitales ambiguos.\n\nLos varones 46,XX gen SRY-negativos tienen alteraciones más leves. Es frecuente que la primera consulta sea por un problema de fertilidad.\n\nEn promedio tienen una altura algo inferior a la normal, indicativo de falta de algunos genes pericentroméricos del gen Y, lo que los diferencia clínicamente del síndrome de Klinefelter.\n\nEl estudio analítico muestra unos niveles de testosterona bajos en la edad adulta, con un patrón de hipogonadismo primario (gonadotrofinas elevadas) de forma independiente del estatus SRY. No hay respuesta de la testosterona al estímulo con hCG, pero sí respuesta de las gonadotrofinas a GnRH, aunque no son test necesarios para el diagnóstico.\n\nPresentan azoospermia en relación con la ausencia de la región genética del factor de azoospermia AZF.\n\nSi no se tratan, los hombres con DSD testicular 46,XX experimentan las consecuencias de la deficiencia de testosterona por un hipogonadismo hipergonadotrófico.\n\nEl tratamiento es similar al de otras causas de deficiencia de testosterona. Después de los 14 años, se inicia el tratamiento con dosis bajas de testosterona i.m. (100-200 mg i.m. mensual, y después cada 2 a 3 semanas). Inducida la androgenización, se continúa con testosterona i.m. en sus formas de cipionato o propionato (100-250 mg cada 2-4 semanas), undecanoato (1 g/10-14 semanas), o preparados transdérmicos en gel o parches.\n\nIniciada la terapia con testosterona, se debe evaluar periódicamente el cumplimiento del tratamiento, su eficacia y la aparición de efectos adversos o contraindicaciones.\n\nDurante el primer año se vigilarán concentraciones de PSA y la exploración prostática, y después se seguirá la pauta estándar para la detección del cáncer de próstata, así como el de mama.\n\nEl aumento del hematocrito que puede seguir al tratamiento con testosterona puede sumarse al síndrome metabólico en la predisposición a eventos cardiovasculares, por lo que también es merecedor de seguimiento. Asimismo, interesa la determinación de pruebas funcionales hepáticas.\n\nOtros efectos adversos a vigilar son el aumento de la agresividad, el empeoramiento de la ginecomastia o el acné.\n\nLas formulaciones en vehículos oleosos son ampliamente usadas y bien toleradas, aunque se han descrito el dolor en el lugar de la inyección o el hematoma, la microembolia pulmonar por aceite y reacciones alérgicas.\n\nInteresa la determinación de la densidad mineral ósea por densitometría ósea\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}